Mohamed Yassine Selected Research

Infections

1/2018

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mohamed Yassine Research Topics

Disease

3	Crohn Disease (Crohn's Disease) 01/2022 - 01/2018
2	Colorectal Neoplasms (Colorectal Cancer) 12/2011 - 03/2010
1	Peanut Hypersensitivity (Peanut Allergy) 05/2022
1	Infections 01/2018
1	Rheumatoid Arthritis 01/2018
1	Neoplasms (Cancer) 12/2011
1	Disease Progression 12/2011

Drug/Important Bio-Agent (IBA)

3	Certolizumab Pegol FDA Link 01/2022 - 01/2018
3	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 01/2018
2	Panitumumab (Vectibix)FDA Link 12/2011 - 03/2010
2	Monoclonal AntibodiesIBA 12/2011 - 03/2010
2	ErbB Receptors (EGF Receptor)IBA 12/2011 - 03/2010
1	AllergensIBA 05/2022
1	PowdersIBA 05/2022
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	Bevacizumab (Avastin)FDA Link 12/2011
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2011
1	Irinotecan (Camptosar)FDA LinkGeneric 12/2011

Therapy/Procedure

2	Therapeutics 01/2021 - 12/2011
1	Immunotherapy 05/2022
1	Transjugular Intrahepatic Portasystemic Shunt 05/2022
1	Injections 01/2018
1	Self Administration (Administration, Self) 01/2018
1	Drug Therapy (Chemotherapy) 12/2011